Loading stock data…
CapsoVision, Inc. (CV)
$7.54+0.02 (+0.27%)
Market ClosedLast close Jun 29
CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
CapsoVision, Inc. in the Healthcare sector is trading at $7.54 with a market capitalization of $341M. Wall Street consensus targets $10.00 (1 analysts), implying a +32.6% move over the next 12 months. The stock is currently 51% below its 52-week high of $15.37, remaining 18.2% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +32.6% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $2.79M↓ | $3.92M↑ | $3.54M↑ | $3.31M↑ | $2.78M |
| Gross Profit | $1.33M↓ | $1.95M↑ | $1.91M↑ | $1.81M↑ | $1.49M |
| Operating Income | -$7.09M↑ | -$7.46M↑ | -$8.02M↓ | -$4.65M↑ | -$5.38M |
| Net Income | -$7.03M↑ | -$7.39M↑ | -$7.92M↓ | -$4.63M↑ | -$5.38M |
Peer Comparison
JNJUNHPFE
Fundamentals
CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. The company offers CapsoCam Plus, a capsule endoscopy system for visualization of t...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$341.25M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-133.40%
Volume
Today's trading volume
263,615
Recent News
CapsoVision Q1 Earnings Call Highlights
CapsoVision (NASDAQ:CV) reported steady first-quarter revenue and said it continues to advance artificial intelligence and capsule endoscopy programs aimed at expanding the use of its gastrointestinal imaging platform. On the company’s first-quarter 2026 earnings call, President and Chief Executive
CapsoVision And 2 Other Growth Stocks With Significant Insider Ownership
The United States market has been flat over the last week but is up 30% over the past year, with earnings forecast to grow by 16% annually. In this environment, growth companies with significant insider ownership can be appealing as they often demonstrate strong commitment from those who know the business best.
CapsoVision Q4 Earnings Call Highlights
CapsoVision (NASDAQ:CV) executives highlighted continued commercial growth for its CapsoCam Plus small-bowel capsule endoscopy product and provided updates on regulatory and clinical milestones for the company’s pipeline during its fourth-quarter and full-year 2025 earnings call. Commercial momentu
CapsoVision Conference: CEO Maps AI-Driven Capsule Endoscopy Roadmap for Colon and Pancreas Screening
CapsoVision (NASDAQ:CV) executives used a fireside chat hosted by Roth Senior Research Analyst Kyle Bauser to outline the company’s origins, its capsule endoscopy platform for small bowel visualization, and development plans for future GI indications including colon and pancreas. Management also dis
Is CapsoVision (NASDAQ:CV) In A Good Position To Deliver On Growth Plans?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...